Re-examining class-I presentation and the DRiP hypothesis

Trends in Immunology

Volumn 35, Issue 4, 2014, Pages 144-152

  Rock, Kenneth L ^a   Farfán Arribas, Diego J ^a   Colbert, Jeff D ^a   Goldberg, Alfred L ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antigen presentation; Defective ribosomal product; MHC class I; Proteasome

Indexed keywords

CYCLOHEXIMIDE; DEFECTIVE RIBOSOMAL PRODUCT; EPSTEIN BARR VIRUS ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME INHIBITOR; PROTEOME; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; PEPTIDE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOPHAGY; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; EFFECTOR CELL; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; EPSTEIN BARR VIRUS; ISOTOPE LABELING; LIGAND BINDING; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOSURVEILLANCE; RIBOSOME;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC SURVEILLANCE; PEPTIDES; PROTEOME; RIBOSOMES;

EID: 84897428027     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2014.01.002     Document Type: Review

References (76)

1. Rock K.L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
2. Zhao J., et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007, 6:472-483.
3. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 2002, 82:373-428.
4. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
5. Pickart C.M., Cohen R.E. Proteasomes and their kin: proteases in the machine age. Nat. Rev. Mol. Cell Biol. 2004, 5:177-187.
6. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 2009, 78:477-513.
7. Ravikumar B., et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 2010, 90:1383-1435.
8. Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 1999, 17:739-779.
9. Trowsdale J., et al. Sequences encoded in the class II region of the MHC related to the "ABC" superfamily of transporters. Nature 1990, 348:741-744.
10. Spies T., et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990, 348:744-747.
11. Shepherd J.C., et al. TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 1993, 74:577-584.
12. Rock K.L., et al. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 2004, 5:670-677.
13. York I.A., et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. 2002, 3:1177-1184.
14. Saric T., et al. An IFN-γ-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 2002, 3:1169-1176.
15. Serwold T., et al. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002, 419:480-483.
16. Rock K.L., et al. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol. 2002, 80:1-70.
17. Michalek M.T., et al. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 1993, 363:552-554.
18. Yewdell J.W., et al. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?. J. Immunol. 1996, 157:1823-1826.
19. Craiu A., et al. Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 1997, 272:13437-13445.
20. Goldberg A.L. Development of proteasome inhibitors as research tools and cancer drugs. J. Cell Biol. 2012, 199:583-588.
21. Kisselev A.F., Goldberg A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 2001, 8:739-758.
22. Henderson R.A., et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992, 255:1264-1266.
23. Goldberg A.L., Dice J.F. Intracellular protein degradation in mammalian and bacterial cells. Annu. Rev. Biochem. 1974, 43:835-869.
24. Etlinger J.D., Goldberg A.L. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc. Natl. Acad. Sci. U.S.A. 1977, 74:54-58.
25. Lacsina J.R., et al. Premature translational termination products are rapidly degraded substrates for MHC class I presentation. PLoS ONE 2012, 7:e51968.
26. Qian S-B., et al. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J. Immunol. 2006, 177:227-233.
27. Seifert U., et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010, 142:613-624.
28. Van Deventer S., Neefjes J. The immunoproteasome cleans up after inflammation. Cell 2010, 142:517-518.
29. Golovina T.N., et al. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J. Immunol. 2005, 174:2763-2769.
30. Lev A., et al. Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6964-6969.
31. Benham A.M., Neefjes J.J. Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation. J. Immunol. 1997, 159:5896-5904.
32. Vijh S., et al. Effect of antigen-processing efficiency on in vivo T cell response magnitudes. J. Immunol. 1998, 160:3971-3977.
33. Sykulev Y., et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996, 4:565-571.
34. Apcher S., et al. Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11572-11577.
35. Yewdell J.W. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 2011, 32:548-558.
36. Wheatley D.N., et al. Kinetics of degradation of "short-" and "long-lived" proteins in cultured mammalian cells. Cell Biol. Int. Rep. 1980, 4:1081-1090.
37. Schubert U., et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000, 404:770-774.
38. Salceda S., Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 1997, 272:22642-22647.
39. Vabulas R.M., Hartl F.U. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science 2005, 310:1960-1963.
40. Cardinaud S., et al. The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS ONE 2010, 5:e8692.
41. Duttler S., et al. Principles of cotranslational ubiquitination and quality control at the ribosome. Mol. Cell 2013, 50:379-393.
42. Reits E.A., et al. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 2000, 404:774-778.
43. Tellam J., et al. Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J. Exp. Med. 2007, 204:525-532.
44. Dolan B.P., et al. Distinct pathways generate peptides from defective ribosomal products for CD8+ T cell immunosurveillance. J. Immunol. 2011, 186:2065-2072.
45. Dolan B.P., et al. MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7025-7030.
46. Yewdell J.W., Nicchitta C.V. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 2006, 27:368-373.
47. Reits E., et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 2003, 18:97-108.
48. Princiotta M.F., et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003, 18:343-354.
49. Wolf B.J., Princiotta M.F. Viral and bacterial minigene products are presented by MHC class I molecules with similar efficiencies. Mol. Immunol. 2011, 48:463-471.
50. Roscoe D.M., et al. Role of de novo protein synthesis in target cells recognized by cytotoxic T lymphocytes specific for vesicular stomatitis virus. J. Virol. 1991, 65:6856-6861.
51. Colbert J.D., et al. Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I. J. Immunol. 2013, 191:5410-5419.
52. Rock K.L., et al. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 1990, 249:918-921.
53. Donohue K.B., et al. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 2006, 119:63-73.
54. Fiebiger B.M., et al. Mature proteins derived from Epstein-Barr virus fail to feed into the MHC class I antigenic pool. Eur. J. Immunol. 2012, 42:3167-3173.
55. Khan S., et al. Cutting edge: neosynthesis is required for the presentation of a T Cell Epitope from a long-lived viral protein. J. Immunol. 2001, 167:4801-4804.
56. Hartl F.U., Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 2009, 16:574-581.
57. Landais E., et al. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen. J. Immunol. 2005, 175:7939-7946.
58. Taylor G.S., et al. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J. Immunol. 2006, 177:3746-3756.
59. Paludan C., et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005, 307:593-596.
60. Milner E., et al. The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol. Cell. Proteomics 2006, 5:357-365.
61. Medicherla B., Goldberg A.L. Heat shock and oxygen radicals stimulate ubiquitin-dependent degradation mainly of newly synthesized proteins. J. Cell Biol. 2008, 182:663-673.
62. Alarcon B., et al. Assembly of the human T cell receptor-CD3 complex takes place in the endoplasmic reticulum and involves intermediary complexes between the CD3-gamma.delta.epsilon core and single T cell receptor alpha or beta chains. J. Biol. Chem. 1988, 263:2953-2961.
63. Farfán-Arribas D.J., et al. Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptides. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:16998-17003.
64. Banaszynski L.A., et al. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 2006, 126:995-1004.
65. Grant E.P., et al. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 1995, 155:3750-3758.
66. Moore M.W., et al. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54:777-785.
67. Netzer N., et al. Innate immune and chemically triggered oxidative stress modifies translational fidelity. Nature 2009, 462:522-526.
68. Dolan B.P., et al. Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands. Cell. Mol. Life Sci. 2011, 68:1481-1489.
69. Frydman J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu. Rev. Biochem. 2001, 70:603-647.
70. Kopito R.R. Biosynthesis and degradation of CFTR. Physiol. Rev. 1999, 79:S167-S173.
71. Connell P., et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 2001, 3:93-96.
72. Gardner R.G., et al. Degradation-mediated protein quality control in the nucleus. Cell 2005, 120:803-815.
73. Heck J.W., et al. Cytoplasmic protein quality control degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and San1. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1106-1111.
74. Bengtson M.H., Joazeiro C.A.P. Role of a ribosome-associated E3 ubiquitin ligase in protein quality control. Nature 2010, 467:470-473.
75. Meusser B., et al. ERAD: the long road to destruction. Nat. Cell Biol. 2005, 7:766-772.
76. Wang F., et al. A cotranslational ubiquitination pathway for quality control of misfolded proteins. Mol. Cell 2013, 50:368-378.